$ARTL
Artelo Biosciences, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Solana Beach, CA
ARTL chart
What traders are saying about $ARTL
Latest postsArtelo Biosciences, Inc. news
- Artelo Biosciences unveils ART26.12, a novel no...
Pluang ·
- Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
Yahoo Finance ·
- Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
Yahoo Finance ·
- Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
Yahoo Finance ·
- Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
Yahoo Finance ·
- Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- Artelo Biosciences Announces Reverse Stock Split
Yahoo Finance ·
- Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
Yahoo Finance ·
- Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
Yahoo Finance ·
- Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
Yahoo Finance ·
- New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
Yahoo Finance ·
- Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
Yahoo Finance ·
Artelo Biosciences, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$12.9M | -$9.8M | -$9.3M | -$10.1M |
| Diluted EPS | $-37.75 | $-54.89 | $-18.80 | – |
| Total assets (year end) | $2.8M | $4.7M | $13.0M | $20.4M |
| Cash and equivalents (year end) | $600,000 | – | – | $6.9M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Artelo Biosciences, Inc.
- Ticker
- ARTL (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Solana Beach, CA
- Incorporated in
- NV
- Fiscal year end
- December 31
- SEC CIK
- 1621221
- Former names
- REACTIVE MEDICAL INC., KNIGHT KNOX DEVELOPMENT CORP.
Frequently asked questions
What exchange is Artelo Biosciences, Inc. listed on?
Artelo Biosciences, Inc. trades on the Nasdaq under the ticker symbol ARTL.
What industry is Artelo Biosciences, Inc. in?
Artelo Biosciences, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Artelo Biosciences, Inc. headquartered?
Artelo Biosciences, Inc.'s business address on file with the SEC is in Solana Beach, CA.
When does Artelo Biosciences, Inc.'s fiscal year end?
Artelo Biosciences, Inc.'s fiscal year ends on December 31.